Abstract
The therapeutic effect of Isosorbide was evaluated in 43 patients (20 males and 23 females) with Meniere's disease.
Vertigo was reduced in 24 patients (87%) after 8 weeks of treatment.
However, in some patients vertigo became worse and nystagumus was observed again.
A follow-up study of 24 patients treated for 2 or more years was analyzed by AAOO and A AO-HNS evaluation criteria.
According to the AAOO criteria, definite attacks were reduced in 9 patients (69%) who were under medication for more than 6 months, and 10 patients (91%) who were under medication for 6 months or less.
According to the AAO-HNS criteria, definite attacks were reduced in 10 patients (77%) who were under medication for more than 6 months, and in 10 patients (91%) who were under medication for 6 months or less. In the follow-up study, hearing was not improved, but tinnitus was reduced in 9 patients (38%).
While under medication, definite attacks still occurred in some patients.
In conclusion, further research is needed to determine the dosage of Isosorbide required for the treatment of Meniere's disease.
